The Potential Health Benefits of the Consciousness Energy Treated Novel Test Formulation on Various Functional Enzyme Biomarkers

Journal: Journal of Genetics and Cell Biology  Web

Published: April 5, 2020 Volume: 3 Issue: 1 Pages: 115-127

ISSN: 2639-3360

Authors: Shirley Theresa Holmlund, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal and Snehasis Jana

Citation: Holmlund ST, Trivedi MK, Branton A, Trivedi D, Nayak G, et al. (2020) The Potential Health Benefits of the Consciousness Energy Treated Novel Test Formulation on Various Functional Enzyme Biomarkers. J Genet Cell Biol, 3(1): 115-127.

  • 12 Views
  • Downloads

Abstract

The study objective was to investigate the effect of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Shirley Theresa Holmlund, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in six different cells. The Biofield Energy Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 115.6% and 53.3% restoration of viable cells at 10 and 25 μg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UTMed + UT-TI group. Moreover, the BT-Med + UT-TI group showed 113.5% and 73.5% restoration of cell viability at 0.1 and 1 μg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 101.1%, 829.8% and 698.9% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 μg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 97.9% and 69.7% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 50 μg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 58.2% in the BT-Med + BT-TI group at 1 μg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 67.4% (at 0.1 μg/mL), 80.4% (at 0.1 μg/mL) and 119.8% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups, respectively compared to the untreated. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 57.6% and 82.5% in the BT-Med + UT-TI group at 25 and 63 μg/mL, respectively; while 123.9% at 10 μg/mL in the BT-Med + BT-TI group compared to untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 53.6% and 59% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 10 μg/mL compared to the untreated. Serotonin level was significantly increased by 85.3% in the UT-Med + BT-TI and BT-Med + BT-TI groups at 0.1 μg/mL as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 245.9% and 211.5% at 10 and 50 μg/mL, respectively in the UT-Med + BT-TI group; while 174.3% (at 10 μg/mL) in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs and brain functional enzymes biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones.Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as heart attack, coronary artery disease, heart failure, arrhythmias, congenital heart disease, cardiomyopathy, Wilson disease, hemochromatosis, cirrhosis, liver cancer, pneumonia, emphysema, chronic bronchitis, asthma, osteoporosis, cystic fibrosis, etc.

Conclusion

The study findings showed that the tested novel test formulation was safe and non-toxic based on the MTT cell viability assay in six tested cells. The treatment group like BT-Med + BT-TI showed 115.6% restoration of cell viability at 10 μg/mL in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the BT-Med + UT-TI group showed 113.5% and 73.5% restoration of cell viability at 0.1 and 1 μg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Additionally, 101.1%, 829.8%, and 698.9% restoration of cell viability at 10 μg/mL in adenocarcinomic human alveolar basal epithelial cells (A549) compared to the untreated group. Alkaline phosphatase (ALP) activity was significantly increased by 97.9% and 69.7% in the UT-Med + BT TI and BT-Med + BT TI groups, respectively at 50 μg/mL compared to the untreated in human bone osteosarcoma cells (MG-63). Moreover, ALP activity was significantly increased by 58.2% in the BT-Med + BT-TI group at 1 μg/mL than untreated group. The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 80.4% (at 0.1 μg/mL) and 119.8% (at 10 μg/mL) in the BT-Med + UT-TI and BT-Med + BTTI groups, respectively compared to the untreated group. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 82.5% (at 63 μg/mL) and 123.9% (at 10 μg/mL) in the BT-Med + UT-TI and BTMed + BT-TI groups, respectively compared to the untreated group. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 59% in the BT-Med + BT-TI group at 10 μg/mL compared to the untreated group. The serotonin level was significantly increased by 85.3% at 0.1 μg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups as compared to the untreated group in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 245.9% and 211.5% at 10 and 50 μg/mL, respectively in the UT-Med + BT-TI group; while 174.3% (at 10 μg/mL) in the BT-Med + UT-TI group compared to the untreated group in MG-63 cells. In conclusion, The Biofield Energy Treatment significantly improved heart, liver, bones, neuronal and lungs functional enzymes biomarkers and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (peripheral artery disease, high blood pressure, congenital heart disease, stroke, congestive heart failure, rheumatic heart disease, carditis, valvular heart disease, thromboembolic disease and venous thrombosis, etc.), hepatic disorders (cirrhosis, Wilson disease, liver cancer, hemochromatosis), and lungs disorders (Asthma, Emphysema, Chronic bronchitis, Pneumonia, Cystic fibrosis). Further, it can be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., liver, kidney, and heart transplants), aging, hormonal imbalance and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Dermatitis, Asthma, Ulcerative Colitis (UC), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Aplastic Anemia, Multiple Sclerosis, Hepatitis, Graves’ Disease, Irritable Bowel Syndrome (IBS), Dermatomyositis, Diabetes, Myasthenia Gravis, Atherosclerosis, Parkinson’s Disease, Systemic, etc., to Lupus Erythematosus (SLE), stress, improve overall health and Quality of Life.